Open Access. Powered by Scholars. Published by Universities.®
Medicinal and Pharmaceutical Chemistry Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Pharmaceutics and Drug Design (3)
- Chemicals and Drugs (2)
- Diseases (2)
- Pharmaceutical Preparations (2)
- Virus Diseases (2)
-
- Amino Acids, Peptides, and Proteins (1)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Chemistry (1)
- Immune System Diseases (1)
- Life Sciences (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Medicinal-Pharmaceutical Chemistry (1)
- Nanomedicine (1)
- Nanotechnology (1)
- Organic Chemicals (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Physical Sciences and Mathematics (1)
- Therapeutics (1)
- Keyword
-
- Prodrugs (2)
- ART (1)
- Antiretroviral Therapy (1)
- BB2r (1)
- Computational (1)
-
- Darunavir (1)
- Docking (1)
- GLUT1 (1)
- Injectables (1)
- Long-acting (1)
- Monocyte-derived macrophages (1)
- Nanoformulation (1)
- Nanoformulations (1)
- PPARγ (1)
- Prostate cancer (1)
- Rilpivirine (1)
- Slow Effective Release Antiretroviral Therapy (LASER ART) (1)
- Tumor-targeted radiopharmaceuticals (1)
- Virtual Screening (1)
Articles 1 - 5 of 5
Full-Text Articles in Medicinal and Pharmaceutical Chemistry
Identification Of More Potent And Efficacious Analogs Of The Novel Host-Derived Immunostimulant Ep67, Abdul Alshammari
Identification Of More Potent And Efficacious Analogs Of The Novel Host-Derived Immunostimulant Ep67, Abdul Alshammari
Theses & Dissertations
EP67 is a human C5a-derived decapeptide agonist of C5a Receptor 1 (C5aR1/CD88) that selectively activates mononuclear phagocytes over neutrophils to stimulate protective innate and adaptive immune responses while potentially minimizing neutrophil-mediated toxicity. Two N-alkyl amino acids Pro7 and N-methyl-Leu8 (nme-Leu8) within EP67 induce structural changes that increase potency and selective activation of mononuclear phagocytes over neutrophils. Cis/trans isomerization at these positions, however, likely limits the activity of EP67 and low coupling efficiency between Pro7 and nme-Leu8 increases scale-up costs for clinical use. Thus, the goals of this study were to …
Computational Studies And Design Of Pparγ And Glut1 Inhibitors, Suliman Almahmoud
Computational Studies And Design Of Pparγ And Glut1 Inhibitors, Suliman Almahmoud
Theses & Dissertations
The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor of the nuclear receptor superfamily that controls the expression of a variety of genes involved in fatty acid metabolism, adipogenesis, and insulin sensitivity. PPARγ is a target for insulin-sensitizing drugs, and it plays a significant function in prostate cancer. PPARγ antagonists have anti-proliferative effects in a broad range of hematopoietic and epithelial cell lines. The ligand binding domain (LBD) of PPARγ is large and has orthosteric and allosteric binding sites. Several PPARγ-ligand co-crystal structures show two bound molecules, one to the orthosteric pocket and a second to the allosteric …
Synthesis And Characterization Of Long Acting Darunavir Prodrugs, Mary Banoub
Synthesis And Characterization Of Long Acting Darunavir Prodrugs, Mary Banoub
Theses & Dissertations
Patient adherence is critical for ART success to ensure adequate viral suppression, therefore, long-acting antiretrovirals are soon replacing current daily regimens. In recent years, two drugs were successfully transformed into long-acting injectables; CAB LA and RPV LA. These long-acting nanoformulations made it possible to abandon the daily pill burden, instead approximately a bimonthly injection of both drugs is enough to suppress and maintain viral load suppression. Our laboratory has been instrumental in transforming FDA-approved and experimental-HIV medications into long-acting slow effective release drugs, also known as LASER ART. LASER ART consists of slow drug metabolism and high permeability and retention …
Synthesis And Characterization Of Long-Acting Rilpivirine Prodrugs, James R. Hilaire
Synthesis And Characterization Of Long-Acting Rilpivirine Prodrugs, James R. Hilaire
Theses & Dissertations
Antiretroviral therapy (ART) requires lifelong daily dosing to suppress viral replication, restore or maintain immune function and improve quality of life. As an alternative, long-acting (LA) antiretrovirals (ARVs) aim to deliver therapeutic drug concentrations over an extended period, ultimately requiring monthly or even more extended dosing intervals. Specifically, the success of recent clinical trials examining LA cabotegravir and rilpivirine (CAB and RPV LA) highlight the advent of these novel HIV-1 therapeutics. Further optimization of LA dosage forms are required and rests upon improving dosing frequency, injection volumes and tissue distribution to viral compartments. To this end, we report the synthesis …
Development Of Approaches Of Tumor Trapping Enhanced Bb2r-Targeted Radiopharmaceuticals For Prostate Cancer, Wenting Zhang
Development Of Approaches Of Tumor Trapping Enhanced Bb2r-Targeted Radiopharmaceuticals For Prostate Cancer, Wenting Zhang
Theses & Dissertations
The Gastrin-Releasing Peptide Receptor (BB2r) has been intensively investigated as a cancer target over the years. Numerous diagnostic and therapeutic BB2r-targeted agents have been developed for various solid tumors, including prostate cancers, due to the high expression level of BB2r on neoplastic relative to normal tissues. The development of those targeted agents have mainly utilized the modified c-terminal of bombesin(BBN), a peptide that has nanomolar binding affinity to human BB2r. However, a major issue that hinders the clinical translational potential of low-molecular weight, receptor-targted agents, is their short residence time at tumor tissues due to the intrinsically high diffusion and …